SQUARE

e-

SQUARE

 
Healthcare online Keeping you up-to-date
VOL.  22     ISSUE: 8  August  2024 Medical Services Department

SQUARE Pharmaceuticals PLC.

Features

EDITORIAL TEAM

OMAR AKRAMUR RAB

MBBS, FCGP, FIAGP,

P G Dip. Business Management

Rubyeat Adnan

MBBS, MPH, CCD

Moshfiqur Rahman

MBBS

EDITORIAL

Dear Doctor,

Hope you are enjoying this healthcare online !
Our current health bulletin issue focused on some latest features like -


"
Migraine and Parkinson's Disease !", "Semaglutide Benefits !", "Alzheimer's Drug !", "Early-life Antibiotics !",  "Skin Allergies !", "Psoriasis Solution !".

In our regular feature, we have some new products information of SQUARE Pharmaceuticals PLC. as well.

We appreciate your feedback !

Click on to reply mode.

Yours sincerely,

 

Editorial Team

Reply Mode      : e-square@squaregroup.com

The views expressed in this publication do not necessarily reflect those of its editor or SQUARE Pharmaceuticals PLC.

 Migraine and Parkinson's Disease !

Study finds no link between migraine and Parkinson's disease

Contrary to previous research, a new study of female participants finds no link between migraine and the risk of developing Parkinson's disease. These results are reassuring for women who have migraine, which itself causes many burdens, that they don't have to worry about an increased risk of Parkinson's disease in the future. The study involved 39,312 female participants with an average age of 55 at the start of the study. A total of 7,321 of the participants reported current or past migraine at the start of the study. The participants were then followed for an average of 22 years. During that time, 685 people reported physician-diagnosed Parkinson's disease. Of those, 128 were people who reported a history of migraine or active migraine, and 557 were people with no migraine. After adjusting for other factors that could affect risk of developing Parkinson's disease as well as migraine, such as age, physical activity, alcohol use and smoking status, researchers found that people with migraine were no more likely to develop Parkinson's disease than those who did not have migraine. This result did not change based on how frequently people had a migraine or whether they experienced an aura before the migraine. An aura is a visual or other sensory disturbance that occurs before the migraine starts, such as seeing bright lights. Since this study involved only female health professionals who were primarily white people, more research is needed to determine whether the results will apply to other groups, including men, women and other races, ethnicities and gender identities. Another limitation of the study is that participants self-reported information on migraine and Parkinson's disease, so it is possible that some information was not accurate. In addition, since Parkinson's disease is often not diagnosed until symptoms are advanced, it's possible that some participants may have developed Parkinson's disease after the end of the study.

SOURCE: American Academy of Neurology, August 2024

Return to top

 Semaglutide Benefits !

 Weight loss drug's heart benefits extend to people with heart failure

The anti-obesity medication semaglutide may help to prevent heart attacks and other major adverse cardiac events among overweight people who have cardiovascular disease, whether or not they also have heart failure, according to a new study. The results follow previous research from the same international team finding that weekly injections of semaglutide were linked to a 20% reduction in major adverse cardiac events (MACE) such as heart attacks and strokes for people with obesity or who were overweight and had cardiovascular disease. The new study, published in The Lancet, found similar cardiovascular benefits for a subgroup of study participants who were also judged to have heart failure. The researchers looked at data from 4,286 people out of a total of 17,605 from the landmark Semaglutide and Cardiovascular Outcomes trial who were randomly assigned either semaglutide or a placebo who were followed up over an average of more than three years. They found that semaglutide was linked to a 28% reduction in major adverse cardiac events (12.3% in the placebo group had such events compared to 9.1% in the semaglutide group), as well as a 24% reduction in cardiovascular disease-related deaths for this subgroup of people with pre-existing heart failure, and a 19% reduction in deaths of any cause. The analysis showed the benefits of semaglutide for people with cardiovascular disease who had obesity or were overweight. This new study finds that, within this group, people with heart failure did just as well as people without in terms of the outcomes we measured. This is important as there were concerns that semaglutide might be harmful for people with a type of heart failure known as reduced ejection fraction, where the heart pumps less blood around the body. The findings show that the benefit of semaglutide was similar regardless of heart failure type. The study looked at data from the landmark SELECT trial the largest and longest clinical trial of the effects of semaglutide on weight in over 17,000 adults who did not have diabetes but who were overweight or had obesity. It was initially prescribed for adults with type 2 diabetes. However, the drug is not yet recommended for this use in the NHS. Its benefits may first need to be compared to those of another new medicine, SGLT2 inhibitors, a diabetes drug also found to have cardiovascular benefits. The exact mechanism through which semaglutide delivers cardiovascular benefits is not known, but may include the drug's positive impacts on blood sugar, blood pressure, and inflammation, as well as direct effects on the heart muscle and blood vessels. The study compared the impact of semaglutide for people with two types of heart failure & preserved ejection fraction, where the heart pumps blood normally but is too stiff to fill properly, and reduced ejection fraction.

SOURCE: Science daily News, August 2024

Return to top

 
 
 Alzheimer's Drug !

Alzheimer's drug may slow down cognitive decline in dementia

Dementia with Lewy bodies is a type of dementia that is similar to both Alzheimer's disease and Parkinson's disease but studies on long-term treatments are lacking. A new study highlights the potential cognitive benefits of cholinesterase inhibitor treatment. Lewy body disease, which includes dementia with Lewy bodies (DLB) and Parkinson's disease with and without dementia, is the second most common neurodegenerative disorder, following Alzheimer's disease. DLB accounts for approximately 10-15 per cent of dementia cases and is characterised by changes in sleep, behaviour, cognition, movement, and regulation of automatic bodily functions. There are currently no approved treatments for DLB, so doctors often use drugs for Alzheimer's disease, such as cholinesterase inhibitors and memantine, for symptom relief. However, the effectiveness of these treatments remains uncertain due to inconsistent trial results and limited long-term data. In the current study, researchers have examined the long-term effects of cholinesterase inhibitors (ChEIs) and memantine compared with no treatment for up to ten years in 1,095 patients with DLB. They found that ChEIs may slow down cognitive decline over five years compared to memantine or no treatment. ChEIs were also associated with a reduced risk of death in the first year after diagnosis. The results highlight the potential benefits of ChEIs for patients with DLB and support updating treatment guidelines. Due to the study's observational nature, no conclusions can be drawn about causality. The researchers did not have data on patient lifestyle habits, frailty, blood pressure, and Alzheimer's disease co-pathology, which may have influenced the findings. Another limitation of the study is that it remains challenging to diagnose DLB accurately. The research was mainly financed by StratNeuro, the Center for Innovative Medicine (CIMED), the KI foundations and the Swedish Research Council.

SOURCE: Science daily News, August 2024

Return to top

 
 
 Early-life Antibiotics !

How early-life antibiotics turn immunity into allergy

Researchers have shown how and why the depletion of microbes in a newborn's gut by antibiotics can lead to lifelong respiratory allergies. The research team identified a specific cascade of events that lead to allergies and asthma, opening many new avenues for exploring potential preventions and treatments. The research finally shows how the gut bacteria and antibiotics shape a newborn's immune system to make them more prone to allergies This is a well-sculpted pathway that can have lasting consequences on susceptibility to chronic disease as an adult. Allergies are a result of the immune system reacting too strongly to harmless substances like pollen or pet dander, and a leading cause for emergency room visits in kids. Normally, the immune system protects us from harmful invaders like bacteria, viruses and parasites. In the case of allergies, it mistakes something harmless for a threat in this case, parasites and triggers a response that causes symptoms like sneezing, itching or swelling. The stage for our immune system's development is set very early in life. Research over the past two decades has pointed toward microbes in the infant gut playing a key role. Babies often receive antibiotics shortly after birth to combat infections, and these can diminish certain bacteria. Some of those bacteria produce a compound called butyrate, which is key to halting the processes uncovered in this research. Now, by studying the process in mice, they have discovered how this works. Mice with depleted gut bacteria who received no butyrate supplement developed twice as many of a certain type of immune cell called ILC2s. These cells, discovered less than 15 years ago, have quickly become prime suspects in allergy development. The researchers showed that ILC2s produce molecules that 'flip a switch' on white blood cells to make them produce an abundance of certain kinds of antibodies. These antibodies then coat cells as a defence against foreign invaders, giving the allergic person an immune system that is ready to attack at the slightest provocation. Every cell, molecule and antibody described along this cascade increases dramatically in number without butyrate to dampen them. Now that researchers know what those other steps are, they have many more potential targets for halting the cascade, even after the supplementation window has closed. With this new understanding, patients can look forward to more effective, long-term solutions that address the root of the problem, paving the way for a future where allergies are managed more effectively, or perhaps avoided altogether.

SOURCE: Science daily News, August 2024

Return to top

 
 
 Skin Allergies !

Dietary fiber in the gut may help with skin allergies

A new study exploring the emerging gut-skin axis has found that microbial fermentation of dietary fiber in the gut can protect against allergic skin disease. The research could potentially lead to novel treatments to prevent or treat allergies. The fermentation of fibre in the gut by bacteria and subsequent production of short-chain fatty acids (SCFAs), in particular butyrate, protected against atopic dermatitis in mice. While it is well established that the gut microbiome shapes the immune system, the influence it has on the skin is less explored. Previous work from the group, and others, has focused on the local health benefits of SCFAs in the gut as well as at distal sites such as the lung and cardiovascular system . It wondered if this might also extend to the skin, which is an area that has not really been investigated. People speculate that diet can influence skin health, but there is not a great deal of science behind this. The researchers fed mice a diet high in fermentable fibre or gave them purified SCFAs. This treatment was profoundly protective against allergic skin inflammation. They labelled the butyrate with isotopes and tracked it in the body & it took only minutes to reach the skin where it enhanced the metabolism of keratinocytes, priming them to mature and produce the key structural components required for a healthy skin barrier. The upshot of this was that the skin barrier was fortified against allergens researcher were using house dust mite allergens & that would normally penetrate the skin barrier, activate the immune system and start an allergic reaction in these models. It turns out the immune system was secondary to this skin barrier function. Actively improving the skin barrier could have protective effects against environmental exposures that cause allergies and perhaps even other skin diseases which are underpinned by a damaged or weak skin barrier. SCFAs could be administered orally or directly on the skin as a cream, bypassing the gut. The fact that short-chain fatty acids can be given topically and are well-tolerated opens up possibilities for the development of preventative strategies or disease-modifying interventions that represents the most significant translational potential of our research.

SOURCE: Science daily News, August 2024

Return to top

 
 
 Psoriasis Solution !

Glycerin is safe, effective in psoriasis 

Patients with psoriasis have reported that glycerin, an inexpensive, harmless, slightly sweet liquid high on the list of ingredients in many skin lotions, is effective at combating their psoriasis and now scientists have objective evidence to support their reports. Scientist found that whether applied topically or ingested in drinking water, glycerin, or glycerol, helps calm the classic scaly, red, raised and itchy patches in their psoriasis model. The studies also provide more evidence of the different ways glycerin enables the healthy maturation of skin cells through four stages that result in a smooth, protective skin layer. Psoriasis is an immune-mediated problem that typically surfaces in young adults in which skin cells instead multiply rapidly, piling up into inflamed patches. The glycerin, a natural alcohol and water attractor known to help the skin look better, also safely helped it function better by helping skin cells mature properly. Topically, glycerin is known to have a soothing, emollient effect. But another key part of its magic, which is its conversion to the lipid, or fat, phosphatidylglycerol, which ultimately regulates the function of keratinocytes, major skin cell type, and suppresses inflammation in the skin. Glycerin gets into the skin through avenues like aquaporin-3, a channel expressed in skin cells, and the MCG scientists have shown that once inside, aquaporin 3 funnels glycerin to phospholipase-D-2, an enzyme that converts fats in the external cell membrane into cell signals, ultimately converting glycerin to phosphatidylglycerol. The topical application of phosphatidylglycerol reduced inflammation and the characteristic raised skin patches in a mouse model of psoriasis. This time they decided to look at the impact of its widely available precursor glycerin. For the new studies, they used imiquimod, which is known to produce psoriasis-like plaques on humans using it for problems like genital warts and some skin cancers, to produce an animal model. The mice either drank the sweet natural alcohol or the scientists applied it topically. Either way, glycerin helped reduce development of the characteristic skin lesions, the scientists report, a finding which helps underline that glycerin works in more than one way to improve the skin condition. Externally, glycerin showed its action as an emollient because even in mice missing phospholipase-D-2, it was beneficial. Additionally, topically it appears to compete with hydrogen peroxide for space inside the aquaporin 3 channel. Hydrogen peroxide is commonly known as a mild antiseptic but we produce it as well and at low levels it's a cell signaling molecule. But at high levels, hydrogen peroxide produces destructive oxidative stress, which can actually cause psoriasis. The scientists found that topical glycerin reduced the levels of hydrogen peroxide entering skin cells. When they added glycerin and hydrogen peroxide at the same time directly to skin cells, they found that glycerin protected against the oxidative stress from hydrogen peroxide.

SOURCE: Science daily News, August 2024

Return to top

 
 

New Products of SQUARE Pharmaceuticals PLC.

Product Methomol TM  
Generic Name Methocarbamol
  Strength 500 mg
  Dosage form Tablet
  Therapeutic Category CNS
Product D-balance O-SolutionTM
Generic Name

Colecalciferol 

Strength 2000 IU/ml
Dosage form Oral Solution
Therapeutic Category Plain Vitamin
Product Pepnor SyrupTM
  Generic Name Jirakadyarista Gastroprokinetic
  Strength 2.64 gm/5 ml
Dosage form Syrup
  Therapeutic Category Gastroprokinetic

Return to top

 

Copyright © 2024 SQUARE Pharmaceuticals PLC. All rights reserved.